Abstract
Abstract. Twelve normal persons and 12 patients with mitral stenosis have been examined with heart catheterization before and during intravenous infusion of Complamin®, 510 mg on an average. There were no significant changes in the following ten parameters: oxygen consumption, arteriovenous oxygen difference, cardiac index, pulmonary arteriolar resistance, systemic arteriolar resistance, pulmonary capillary venous pressure, pressure in the pulmonary artery and systolic arterial pressure, heart rate and stroke volume. There was a trend to reduction in the systolic arterial pressure. No rise of the mean pressure in wedged position and in the pulmonary artery was observed in normal persons or in patients with mitral stenosis. This study gives no support for the opinion stated by the manufacturer that Complamin® is contraindicated in patients with mitral valvular disease.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
